DOI: 10.1097/01.COT.0000295410.34692.2f

,  

Issn Print: 0276-2234

Publication Date: 2006/05/10


Print

Vitamin D May Lower Risk of Thromboembolic Events in Prostate Cancer

    loading  Checking for direct PDF access through Ovid

Excerpt

High doses of vitamin D may reduce the risk of thromboembolic events in patients with androgen-independent prostate cancer, according to a post-hoc analysis of the ASCENT (Androgen-Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere) trial.
“While not ready for prime time, the finding, if confirmed, will open the door to a new way of preventing blood clots in cancer patients,” said Tomasz M. Beer, MD, Associate Professor of Medicine at Oregon Health & Science University Cancer Institute.
“Thromboembolic events are a common issue with prostate cancer patients undergoing chemotherapy,” he explained. “The 9% rate observed in the chemotherapy plus placebo arm of the ASCENT trial is pretty typical.”
The ASCENT study showed that the combination of docetaxel (Taxotere) plus high-dose vitamin D (DN-101, calcitriol) increased survival by 49%, compared with docetaxel plus placebo in men with androgen-independent prostate cancer.

Related Topics

    loading  Loading Related Articles